PulseAugur
EN
LIVE 10:29:43

Merck, Moderna melanoma vaccine shows promise in Phase 3 trial

By PulseAugur Editorial · [3 sources] ·

Merck and Moderna have announced promising results from a Phase 3 clinical trial for their personalized mRNA vaccine, intismeran autogene, when used in combination with Merck's Keytruda immunotherapy for melanoma patients. The trial, which included 1,137 patients with high-risk melanoma whose tumors had been surgically removed, showed statistically significant improvements, with patients receiving the vaccine and Keytruda experiencing longer periods without cancer recurrence or spread compared to those receiving Keytruda alone. This marks a potential breakthrough for mRNA-based cancer therapies and has led to a substantial increase in Moderna's stock price. AI

IMPACT This marks a significant step for mRNA-based cancer therapies, potentially establishing a new treatment paradigm for melanoma and validating the technology's application beyond infectious diseases.

RANK_REASON Positive Phase 3 clinical trial results for a novel mRNA cancer therapy.

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 3 sources. How we write summaries →

Merck, Moderna melanoma vaccine shows promise in Phase 3 trial

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Positive Phase 3 clinical trial results for a novel mRNA cancer therapy.
Source corroboration
3 independent sources
Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics
model release, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
56 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.
Coverage growth since scoring
+1 source(s) since last score
New sources have picked up this story since our last re-score. Score will update on the next scoring pass.

Full methodology in our editorial standards.

COVERAGE [3]

  1. SCMP — Tech TIER_1 (CA) · Agence France-Presse ·

    Merck, Moderna claim encouraging melanoma vaccine trial results

    US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically m…

  2. Fortune TIER_1 English(EN) · Catherina Gioino ·

    Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

    The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

  3. Axios Technology TIER_1 English(EN) · Tina Reed ·

    Moderna and Merck shares soar on mRNA cancer vaccine

    <p>Moderna and Merck shares soared on Wednesday after the companies said a personalized <a href="https://www.axios.com/2024/05/07/how-mrna-vaccines-could-be-personalized-cancer-cures" target="_blank">mRNA treatment</a> hit its target of preventing skin cancer from recurring or sp…

RELATED ENTITIES

RELATED TOPICS